cyclic adenosine monophosphate

Cyclic AMP (cAMP) (Adenosine 3',5'-cyclophosphate) combined with vitamin C treatment of children with viral myocarditis has exact curative effect, and it can improve cardiac function of patients and improve immune function.

cAMP sodium(Cyclic adenosine monophosphate sodium) is a derivative of adenosine triphosphate (ATP) and a cellular second messenger. It transmits signals within cells that are carried by primary messengers (such as adrenaline) unable to enter the cell, performing crucial regulatory functions.

Gizzerosine 2HCl, a substance produced during the heat treatment of fishmeal, induces histopathological lesions in broiler chicks and increases intracellular cyclic adenosine-3',5'-monophosphate levels in isolated chickens of origin.

Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.

Salbutamol (Albuterol) stimulates beta2-adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of ATP to cyclic-3', 5'-adenosine monophosphate (cAMP). Salbutamol Sulfate is the sulfate salt of the short-acting sympathomimetic agent albuterol, a 1:1 racemic mixture of (R)-albuterol and (S)-albuterol with bronchodilator activity. Increased cAMP concentrations relax the bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells. To a lesser extent, Salbutamol stimulates beta1-adrenergic receptors, thereby increasing the force and rate of myocardial contraction.

Ritodrine hydrochloride (NSC 291565) binds to and activates beta-2 adrenergic receptors of myometrial cells in the uterus, which decreases the intensity and frequency of uterine contractions. Ritodrine hydrochloride (NSC 291565) is a phenethylamine derivative with tocolytic activity. Specifically, Ritodrine hydrochloride (NSC 291565) probably activates adenyl cyclase, thereby increasing production of cyclic adenosine monophosphate (cAMP), which in turn enhances the efflux of calcium from vascular smooth muscle cells. A lack of intracellular calcium prevents uterine myometrial contractions. In addition, this agent may directly inactivate myosin light chain kinase, a critical enzyme necessary for the initiation of muscle contractions.

Euchrestaflavanone A is a useful organic compound for research related to life sciences and the catalog number is T124187.

TSHR antagonist S37a is a selective, orally bioavailable TSHR (thyroid-stimulating hormone receptor) antagonist that inhibits TSH-induced cyclic adenosine monophosphate (cAMP) in TSHR-expressing HEK 293 cells, suitable for studying Graves' orbitopathy.

Lixazinone is a cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) inhibitor and a cardiac enhancer.

Lixazinone sulfate anhydrous is an inhibitor of cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) and acts as a cardiac enhancer.

Lixazinone sulfate is a cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) inhibitor with cardiotonic properties.

Trequinsin HCl is a phosphodiesterase (PDE) 3 inhibitor dependent on cyclic adenosine monophosphate (cAMP). It facilitates the accumulation of cAMP and enhances cell membrane capacitance.

GLP-1R agonist 27 (compound 21) is a potent and orally active GLP-1R agonist. It enhances the accumulation of cyclic adenosine monophosphate (cAMP), reduces blood glucose levels, and decreases food intake. GLP-1R agonist 27 shows potential for research in obesity and type 2 diabetes mellitus (T2DM).

PDE10A-IN-5 (Compound A30) is an orally active inhibitor of phosphodiesterase 10A (PDE10A) with an IC50 value of 3.5 nM. By inhibiting PDE10A, it activates the cyclic adenosine monophosphate (cAMP)-related signaling pathway, exhibiting activity against pulmonary vascular remodeling. This compound is applicable to research in the field of pulmonary arterial hypertension.

6-Bnz-cAMP (N6-Benzoyl-cAMP) is a derivative of cyclic adenosine monophosphate (cAMP) known as an effective inhibitor of the bTREK-1 potassium channel. It strongly suppresses the bTREK-1 potassium channel through a mechanism independent of protein kinase A (PKA). Additionally, 6-Bnz-cAMP can be utilized to investigate potential signaling proteins within the cAMP signaling pathway.

Naphthol AS-MX phosphate (NASTRp) is a small-molecule inhibitor targeting the CREB (cyclic adenosine monophosphate response element-binding protein)-CBP (CREB-binding protein) transcription factor complex. It exhibits antitumor activity against lung cancer cells by inhibiting tumor cell proliferation (IC50=3.701 μmol/L), colony formation, and anchorage-independent growth in soft agar. This compound is valuable for studying KRAS-mutant lung cancer, particularly in cases of chemotherapy resistance and poor prognosis.

2-MeSADP (2-Methylthioadenosine diphosphate; 2-Methylthio-ADP) is a potent agonist of purinergic (P2Y) receptors, displaying EC50 values of 19 nM for human P2Y13, 6.2 nM for mouse P2Y13, and 5 nM for human P2Y12. It also has pEC50 values of 8.29 for human P2Y1 and 5.75 for rat P2Y6. 2-MeSADP induces platelet aggregation and morphological changes, while inhibiting the accumulation of cyclic adenosine monophosphate in platelets in the presence of prostaglandin E1.

GLP-1R agonist 32 (Compound 111) is an orally active and potent GLP-1R agonist with an EC50 value of 0.017 nM. It stimulates the production of cyclic adenosine monophosphate (cAMP) by activating GLP-1R, which enhances insulin secretion, suppresses glucagon release, and delays gastric emptying to regulate blood glucose levels. GLP-1R agonist 32 shows potential for research in type 2 diabetes, obesity, and related metabolic disorders.

XL-3158 is an orally active inhibitor of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) with human cGAS IC50 of 11.1 μM and murine cGAS IC50 of 2.19 μM. It binds both allosteric and orthosteric sites, stabilizing the inactive closed conformation of the enzyme, thereby weakening cGAS interaction with DNA. By targeting phase separation, XL-3158 effectively penetrates cells, reduces intracellular cGAS local concentration through inhibition of aggregate formation, and shows no significant cytotoxicity at effective concentrations, making it suitable for subsequent cellular function experiments. XL-3158 overcomes species selectivity barriers, presenting a candidate drug for cGAS-dependent inflammatory diseases.

PDE4-IN-29 (Compound 55) is an orally active and selective inhibitor of PDE4, targeting subtypes such as PDE4A1, PDE4B2, and PDE4D3, with an IC50 value for PDE4D3 of less than 5 nM. It inhibits the degradation of cyclic adenosine monophosphate (cAMP), elevating intracellular cAMP levels and suppressing the release of inflammatory mediators like TNF-α. PDE4-IN-29 holds potential for research in inflammatory diseases such as psoriasis, atopic dermatitis, and chronic obstructive pulmonary disease.

CGRP antagonist 7 is a potent calcitonin gene-related peptide receptor (CGRP) antagonist with a Ki value of 0.029 nM. It effectively inhibits CGRP receptor-mediated cyclic adenosine monophosphate (cAMP) production, with an IC50 value of 1.5 nM. This compound is useful in migraine research.

G3-YSD is a G3 terminal Y-shaped short DNA and functions as a cyclic guanosine-adenosine monophosphate synthase (cGAS) agonist. It serves as a minimal immunostimulatory DNA motif, capable of activating the DNA sensor cGAS, which induces type I interferon in a manner dependent on structure and sequence. G3-YSD is applicable for detecting HIV-1 single-stranded DNA.

PDE7 inhibitor S14 is a cell-permeable PDE7 inhibitor that acts by targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element-binding protein (CREB) pathway.

Griseolic acid is a cyclic adenosine 3',5'-monophosphate phosphodiesterase II inhibitor.